Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions

Clinical Chemistry and Laboratory Medicine

Volumn 38, Issue 12, 2000, Pages 1271-1275

  Jung, K ^a   Lein, M ^a   Brux, B ^a   Sinha, P ^a   Schnorr, D ^a   Loening, S A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Free prostate specific antigen; Prostae cancer; Prostate specific antigen; 1 Antichymotrypsin complexed prostatespecific antigen

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ISOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

ACCURACY; ARTICLE; BLOOD SAMPLING; BLOOD STORAGE; CALCULATION; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYOPRESERVATION; FREEZING; HUMAN; IMMUNOASSAY; LABORATORY DIAGNOSIS; MALE; MATERIALS HANDLING; MEASUREMENT; MOLECULAR STABILITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; QUANTITATIVE ASSAY; SERUM; THAWING; THERMOREGULATION;

ALPHA 1-ANTICHYMOTRYPSIN; BLOOD CHEMICAL ANALYSIS; FREEZING; HUMANS; IMMUNOASSAY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; TEMPERATURE; TIME FACTORS;

EID: 0034507715     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/cclm.2000.200     Document Type: Article

References (28)

1. 1-antichymotrypsin as an indicator of prostate cancer
2. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
3. 1-antichymotrypsin complex
4. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum
5. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer
6. Development of an immunoassay specific for the PSA-ACT complex without the problem of high background
7. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: Studies in serum and plasma samples
8. Development of monoclonal antibodies specific for the PSA-ACT complex and their incorporation into an immunoassay
9. Measurement of prostate-specfic antigen by radioimmunoassay
10. Analytical and physiological characteristics of prostate-specific antigen and prostatic acid phosphatase in serum compared
11. Storage conditions for serum for estimating prostate-specific antigen
12. 1-antichymotrypsin
13. Two-year stability of free and total PSA in frozen serum samples
14. Preanalytical determinants of total and free prostate-specific antigen and their ratio: Blood collection and storage conditions
15. Reduced stability of prostate-specific antigen after long-term storage of serum at-20 degrees
16. 1-antichymotrypsin in blood samples
17. Lyophilized PSA-ACT complex is stable
18. 1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared to total PSA and percentage free PSA
19. Multicentre evaluation of a new fully automated enzyme immunoassay for total prostate-specific antigen
20. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions
21. Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures
22. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia
23. Complexed prostate specific prostate antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
24. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
25. 1-protease inhibitor in vitro
26. 1-protease inhibitor in serum
27. Complex formation between PSA isoenzymes and protease inhibitors
28. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors